A Modular, Multipart, Multiarm, Open-label, Phase I / Phase IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies

Trial Profile

A Modular, Multipart, Multiarm, Open-label, Phase I / Phase IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs CT-7001 (Primary)
  • Indications Acute myeloid leukaemia; Breast cancer; Cancer; Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Carrick Therapeutics
  • Most Recent Events

    • 05 Dec 2017 New trial record
    • 30 Nov 2017 According to a Carrick Therapeutics media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top